Skip to main content

Table 1 Characteristics of the full study population and ER+ and ER- subgroups

From: Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort

 

Full population

ER+ cases

ER- cases

n a

2006

1620

386

Baseline characteristics, median (range), or n (%))

 Age at blood collection, years

56.6 (26.7, 75.5)

56.8 (33.4, 75.5)

54.9 (26.7, 72.1)

 Age at menarche, years*

13.0 (8.0, 20.0)

13.0 (8.0, 20.0)

13.0 (9.0, 20.0)

Menopausal status at blood collection

  Premenopausal

463 (23%)

352 (22%)

111 (29%)

  Postmenopausal

1543 (77%)

1268 (78%)

275 (71%)

   PMH use at blood collectionb

753 (49%)

623 (49%)

130 (47%)

   Age at menopause, yearsb*

50.0 (27.0, 63.0)

50.0 (27.0, 63.0)

49.0 (30.0, 59.0)

Full term pregnancy, ever*

1693 (86%)

1356 (85%)

337 (89%)

  Age at first term pregnancy, yearsc*

25.0 (16.0, 44.0)

25.0 (16.0, 44.0)

24.0 (16.0, 38.0)

BMI, kg/m2

24.4 (13.8, 49.1)

24.5 (13.8, 49.1)

24.0 (16.6, 45.4)

sRANKL concentrations (pmol/L)a

0.11 (0.005, 1.67)

0.11 (0.005, 1.67)

0.11 (0.005, 0.58)

OPG concentrations (pmol/L)

9.86 (2.96, 31.97)

9.95 (2.96, 31.97)

9.59 (3.14, 21.38)

sRANKL/OPG ratio a

0.01 (0.0002, 0.17)

0.01 (0.0002, 0.17)

0.01 (0.0002, 0.09)

Breast cancer characteristics

 Age at diagnosis, years

60.9 (35.2, 83.6)

61.3 (37.1, 83.6)

59.1 (35.2, 80.6)

 Time between blood collection and diagnosis, years

4.7 (0.02, 11.7)

4.8 (0.02, 12.0)

4.5 (0.04, 11.5)

Progesterone receptor subtype at diagnosis*

  PR+

984 (67%)

926 (80%)

58 (18%)

  PR-

494 (33%)

236 (20%)

258 (82%)

Breast cancer stage at diagnosis*

  Localized

1089 (68%)

877 (68%)

212 (66%)

  Non-localizedd

524 (32%)

415 (32%)

109 (34%)

Deaths & follow-up

 Number of deaths of any cause

421 (21.0%)

310 (19%)

111 (29%)

 Number of breast cancer deaths

250 (12.5%)

165 (10%)

85 (22%)

 Duration of follow-up, yearse

10.9 (0.05, 19.1)

11.0 (0.05, 19.1)

10.3 (0.08, 18.3)

 Overall survival time, yearsf

6.5 (0.08, 18.5)

7.2 (0.14, 18.5)

4.1 (0.08, 15.2)

 Breast cancer-specific survival time, yearsg

5.0 (0.8, 15.2)

6.4 (0.7, 14.8)

3.4 (0.08, 15.2)

  1. an = 1970 for sRANKL analyses and n = 1965 for sRANKL/OPG ratio analyses, comparable distribution of baseline characteristics; b Among postmenopausal women; c among women with at least one completed term pregnancy; d non-localized breast cancer includes regional (n = 401), distant (n = 15), and unspecified (n = 108) metastatic sites; e time between diagnosis and end of follow-up; f Time between diagnosis and death, among those who died of any cause; g Time between diagnosis and death, among those who died of breast cancer. * Missing data: Age at menarche: 36 cases (1.8%); age at menopause: 477 cases (31%); ever FTP: 30 cases (1.5%); age at first FTP: 7 cases (0.4%); PR status: 528 cases (26%); breast cancer stage: 393 cases (19.6%)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us